<DOC>
	<DOCNO>NCT02464306</DOCNO>
	<brief_summary>A prospective study ass efficacy safety fidaxomicin Solid Organ Transplant ( SOT ) recipient ( heart , lung , kidney , liver , kidney-pancreas , pancreas ) first-episode Clostridium difficile infection ( CDI ) .</brief_summary>
	<brief_title>Fidaxomicin Versus Standard Care Therapy Solid Organ Transplant Recipients With Clostridium Difficile Infection</brief_title>
	<detailed_description>Patients treat fidaxomicin 200 mg PO twice daily 10 day . The rate sustain clinical response ( SCR ; cure without recurrence 30 day ) assess compare historical cohort SOT recipients receive standard care therapy CDI institution . The data historical control group collect separate IRB-approved protocol . Standard care therapy consider oral intravenous metronidazole / oral vancomycin . The study power show non-inferiority fidaxomicin compare standard care treatment SOT recipient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>Age 18 great 85 year SOT recipient ( lung , heart , kidney , liver , kidneypancreas , pancreas ) First episode CDI Receiving additional therapy activity C. difficile ( oral bacitracin , fusidic acid , and/or rifaximin ) Toxic megacolon Ileus significant abdominal distension Hypotension vasopressor requirement History inflammatory bowel disease Pregnancy Decisionally challenge Prisoners &gt; 4 dos metronidazole treatment C. difficile previous 7 day &gt; 4 dos oral vancomycin previous 7 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recipient</keyword>
</DOC>